Literatur
- 1
Hasslacher C, Ritz E, Wahl P et al.
Similar risks of nephropathy in patients with type I or type II diabetes mellitus.
Nephrol Dial Transplant.
1989;
4
859-863
- 2
Verhave J C, Hillege H L, Burgerhof J G PREVEND Study Group et al.,.
Cardiovascular risk factors are differently associated with urinary albumin excretion
in men and women.
J Am Soc Nephrol.
2003;
14
1330-1335
- 3
Hasslacher C, Wolf G, Kempe P et al.
Diabetische Nephropathie.
Diabetologie.
2008;
3 (Suppl. 2)
S143-S146
- 4
Parving H H, Hommel E, Mathiesen E et al.
Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy
in patients with insulin dependent diabetes.
Br Med J (Clin Res Ed).
1988;
296
156-160
- 5
Lurbe E, Redon J, Kesani A et al.
Increase in nocturnal blood pressure and progression to microalbuminuria in type 1
diabetes.
N Engl J Med.
2002;
347
797-805
- 6
Redon J, Cifkova R, Laurent S et al.
Mechanisms of hypertension in the cardiometabolic syndrome.
J Hypertens.
2009;
27
441-451
- 7
Lang F, Klingel K, Wagner C A et al.
Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic
nephropathy.
Proc Natl Acad Sci U S A.
2000;
97
8157-8162
- 8
Perrotti N, He R A, Phillips S A et al.
Activation of serum- and glucocorticoid-induced protein kinase (Sgk) by cyclic AMP
and insulin.
J Biol Chem.
2001;
276
9406-9412
- 9
Tiwari S, Riazi S, Ecelbarger C A.
Insulin's impact on renal sodium transport and blood pressure in health, obesity,
and diabetes.
Am J Physiol Renal Physiol.
2007;
293
F974-F984
- 10
Boini K M, Hennige A M, Huang D Y et al.
Serum- and glucocorticoid-inducible kinase 1 mediates salt sensitivity of glucose
tolerance.
Diabetes.
2006;
55
2059-2066
- 11
Ohashi K, Kihara S, Ouchi N et al.
Adiponectin replenishment ameliorates obesity-related hypertension.
Hypertension.
2006;
47
1108-1116
Erratum in: Hypertension 2007; 49: e14
- 12
Bakris G L, Williams M, Dworkin L et al.
Preserving renal function in adults with hypertension and diabetes: A consensus approach.
National Kidney Foundation Hypertension and Diabetes Executive Committees Working
Group.
Am J Kidney Dis.
2000;
36
646-661
- 13
ACCORD Study Group .
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
N Engl J Med.
2010;
362
1575-1585
- 14
Eijkelkamp W B, Zhang Z, Remuzzi G et al.
Albuminuria is a target for renoprotective therapy independent from blood pressure
in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction
of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
J Am Soc Nephrol.
2007;
18
1540-1546
- 15
de Galan B E, Perkovic V, Ninomiya T ADVANCE Collaborative Group et al.,.
Lowering blood pressure reduces renal events in type 2 diabetes.
J Am Soc Nephrol.
2009;
20
883-892
- 16
Appel L J, Wright Jr J T, Greene T AASK Collaborative Research Group et al.,.
Intensive blood-pressure control in hypertensive chronic kidney disease.
N Engl J Med.
2010;
363
918-929
- 17
Holman R R, Paul S K, Bethel M A et al.
10-year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med.
2008;
359
1577-1589
- 18
Ott P, Benke I, Stelzer J et al.
„Diabetes in Germany” (DIG) Study. A prospective 4-year-follow-up study on the quality
of treatment for type 2 diabetes in daily practice.
Dtsch Med Wochenschr.
2009;
134
291-297
- 19
Abuissa H, Jones P G, Marso S P et al.
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention
of type 2 diabetes: a meta-analysis of randomized clinical trials.
J Am Coll Cardiol.
2005;
46
821-826
- 20
Elliott W J, Meyer P M.
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.
Lancet.
2007;
369
201-207
- 21
Lewis E J, Hunsicker L G, Bain R P et al.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The
Collaborative Study Group.
N Engl J Med.
1993;
329
1456-1462
- 22
Ruggenenti P, Fassi A, Ilieva A P Bergamo Nephrologic Diabetes Complications Trial
(BENEDICT) Investigators et al.,.
Preventing microalbuminuria in type 2 diabetes.
N Engl J Med.
2004;
351
1941-1951
- 23
Mauer M, Zinman B, Gardiner R et al.
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
N Engl J Med.
2009;
361
40-51
- 24
Perkins B A, Ficociello L H, Silva K H et al.
Regression of microalbuminuria in type 1 diabetes.
N Engl J Med.
2003;
348
2285-2293
- 25
Casas J P, Chua W, Loukogeorgakis S et al.
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs
on renal outcomes: systematic review and meta-analysis.
Lancet.
2005;
366
2026-2033
Review
- 26
Barnett A H, Bain S C, Bouter P Diabetics Exposed to Telmisartan and Enalapril Study
Group et al.
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes
and nephropathy.
N Engl J Med.
2004;
351
1952-1961
- 27
Bakris G, Burgess E, Weir M AMADEO Study Investigators et al.,.
Telmisartan is more effective than losartan in reducing proteinuria in patients with
diabetic nephropathy.
Kidney Int.
2008;
74
364-369
- 28
Brenner B M, Cooper M E, de Zeeuw D RENAAL Study Investigators et al.,.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy.
N Engl J Med.
2001;
345
861-869
- 29
Mann J F, Schmieder R E, Dyal L TRANSCEND (Telmisartan Randomised Assessment Study
in ACE Intolerant Subjects with Cardiovascular Disease) Investigators et al.,.
Effect of telmisartan on renal outcomes: a randomized trial.
Ann Intern Med.
2009;
151
1-10
W 1–2
- 30
Mann J F, Schmieder R E, McQueen M ONTARGET investigators et al.,.
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk
(the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Lancet.
2008;
372
547-553
- 31
Ingelfinger J R.
Aliskiren and dual therapy in type 2 diabetes mellitus.
N Engl J Med.
2008;
358
2503-2505
- 32
Parving H H, Persson F, Lewis J B AVOID Study Investigators et al.,.
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
N Engl J Med.
2008;
358
2433-2446
- 33
Jamerson K, Weber M A, Bakris G L ACCOMPLISH Trial Investigators et al.,.
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med.
2008;
359
2417-2428
- 34
Sever P S, Dahlöf B, Poulter N R ASCOT investigators et al.,.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients
who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian
Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised
controlled trial.
Lancet.
2003;
361
1149-1158
- 35
Bakris G L, Sarafidis P A, Weir M R ACCOMPLISH Trial investigators et al.
Renal outcomes with different fixed-dose combination therapies in patients with hypertension
at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis
of a randomised controlled trial.
Lancet.
2010;
375
1173-1181
Priv.-Doz. Dr. med. B. Friedrich
Nephrologische Gemeinschaftspraxis Leonberg
Steinbeisstraße 4–6
71229 Leonberg
Email: bjoern.friedrich1@gmx.de
